Please assess the completion status of the following clinical trial:

Trial Title: Effect of Metformin on Frailty in 12 Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 60 years~* Stable CAD~* Prediabetes (one of the following criteria should be met)~  * Fasting plasma glucose: 100-126 mg/dL~ * HbA1C: 5.7-6.4~* Frailty (Short Physical Performance Battery: Score \<9)~* Able to return for follow-up~* Written informed consent~Exclusion criteria:~* Pre-existing or new-onset diabetes~* Any active malignancy, hematological disorder, post organ transplant, immunocompromised~* Cancer requiring treatment in the past 3 years (other than non-melanoma skin cancer)~* Dementia \[mini mental state examination (MMSE \<20)\]~* Disability (need for assistance in \>2 of any six activities on Katz activities of daily living (ADL)46~* Prior stroke with disability~* Acute coronary syndrome \<3months or participating in cardiac rehabilitation~* Severe Parkinson's~* Hepatic insufficiency and/or chronic liver disease (cirrhosis)~* Chronic kidney disease (GFR \< 45 mL/min)~* Taking metformin for any indication~* Acute alcohol intoxication~* Known hypersensitivity to metformin hydrochloride~* Acute/chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: EXPERIMENTAL): Metformin 500mg tablet by mouth, every 6 to 8 hours for one year
- Placebo (Type: ACTIVE_COMPARATOR): Placebo by mouth every 6 to 8 hours for one year

Based on this trial design, predict the completion outcome and termination type (if applicable).